SEHK:6990Biotechs
A Look At Kelun-Biotech’s Valuation As SKB103 Gains China Regulatory Green Light
Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) just received clearance from China’s drug regulator to begin clinical development of SKB103, its first TAA PD L1 bispecific antibody drug conjugate for advanced solid tumors.
See our latest analysis for Sichuan Kelun-Biotech Biopharmaceutical.
The SKB103 news arrives after a strong run in the shares, with a 30 day share price return of 30.37% and a year to date share price return of 25.69%. The 1 year total shareholder return of 108.06%...